8-K: Actuate Therapeutics Unveils Compelling Phase 2 Data for Elraglusib in Pancreatic Cancer, Signaling Major Advance

Actuate Therapeutics, Inc. announced positive topline Phase 2 data for its drug elraglusib in combination with gemcitabine/nab-paclitaxel for first-line metastatic pancreatic cancer, demonstrating a significant overall survival benefit and high tolerability.

Summary

• Actuate Therapeutics, Inc. hosted a Key Opinion Leader (KOL) event on May 31, 2025, to review topline Phase 2 (Actuate-1801 Part 3B) data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line metastatic pancreatic cancer (mPDAC).
• The study demonstrated a significant improvement in overall survival (OS) for patients receiving elraglusib plus GnP.
• In the modified intent-to-treat population (patients completing at least one cycle), the median overall survival increased to approximately 12.5 months, representing a 4-month benefit compared to the 8.5 months observed in the control arm of the mPDAC study.
• The hazard ratio for OS in this evaluable population was notably strong, with panelists highlighting it as starting with a 'five' (implying less than 0.5), which is significantly better than the typical 0.7-0.8 seen in pancreatic cancer trials.
• Elraglusib, a GSK-3 beta inhibitor, demonstrated a multifaceted mechanism of action, including inhibition of epithelial-mesenchymal transition (EMT), alteration of immune function (augmentation of CD8+ T cells, NK cell activation, decrease in MDSCs), and inhibition of NF-kappa B.
• Despite similar progression-free survival (PFS) between arms, the OS benefit is attributed to the drug's immunomodulatory effects, leading to a 'post-progression benefit' and a durable 'tail of the curve' in survival.
• The drug was reported to be very tolerable in combination with chemotherapy, with patients often feeling 'back to their normal self,' despite transient visual disturbances and manageable neutropenia that did not lead to febrile neutropenia or sepsis.
• A potential biomarker, CXCL2, was identified, with higher baseline levels associated with improved survival in the elraglusib arm, suggesting a way to identify patients most likely to benefit.
• The company is developing an oral tablet formulation of elraglusib, showing greater than 95% bioavailability in preclinical testing, which could facilitate longer-term and home-based treatment.

Sentiment

Score: 9

Explanation: The document conveys highly positive clinical trial results for elraglusib in a disease with significant unmet medical need. The demonstrated overall survival benefit, favorable safety profile, and broad mechanism of action are compelling. While there is a going concern warning, the strong clinical data significantly de-risks future capital raises and potential regulatory approval, leading to a very positive sentiment.

Positives

• Demonstrated a significant overall survival benefit of approximately 4 months in first-line metastatic pancreatic cancer patients who completed at least one cycle of treatment, a rare achievement in this difficult disease.
• The drug, elraglusib, showed high tolerability when combined with gemcitabine/nab-paclitaxel and FOLFIRINOX, with patients reporting improved quality of life and feeling 'back to their normal self'.
• Elraglusib exhibits a multifaceted mechanism of action, targeting key pathways such as EMT, immune modulation (increasing CD8+ T cells and NK cells, decreasing MDSCs), and NF-kappa B inhibition, which is crucial for pancreatic cancer's complex biology.
• The Phase 2 trial was described as 'very well powered' and '50% of a Phase 3 trial, size wise,' indicating robust data for a Phase 2 study.
• Identification of a potential biomarker, CXCL2, suggests the possibility of patient selection for optimized treatment outcomes.
• The development of an oral formulation with high bioavailability (over 95% in preclinical) promises greater convenience and potential for long-term maintenance therapy.
• The observed 'tail of the curve' in overall survival, despite similar PFS, indicates a durable immunomodulatory effect, a pattern seen with successful immunotherapies.

Negatives

• Approximately 15% of patients experienced an early drop-off in the first two months of the study, likely due to poor underlying biology (e.g., low albumin, aggressive basal subtypes, poor performance status).
• Transient visual disturbances (blue/black hue, lasting a few hours) were observed, though not considered dose-limiting or lifestyle-altering.
• Increased rates of neutropenia were noted, although this did not translate into febrile neutropenia or sepsis and was manageable through chemotherapy dose adjustments.

Risks

• Preliminary and unpublished data may be subject to change and further interpretation following the availability of more data or a more comprehensive review.
• Clinical trial data are subject to differing interpretations and assessments by regulatory authorities and within the medical community.
• Clinical and preclinical drug development involves a lengthy and expensive process with uncertain timelines and outcomes.
• Results of prior preclinical studies and early clinical trials are not necessarily predictive of future results.
• Elraglusib may not achieve positive clinical results or favorable preclinical results in future studies.
• The company may not be able to make regulatory submissions or receive regulatory approval on a timely basis, if at all.
• The company may not successfully enroll additional patients or establish or advance plans for further development, including through conversations with the FDA or EMA and the standards such bodies may impose.
• Elraglusib could be associated with side effects, adverse events, or other properties or safety risks, which could delay or preclude regulatory approval, cause suspension or discontinuation of clinical trials, or result in other negative consequences.
• Reliance on third parties to conduct non-clinical studies and clinical trials poses inherent risks.
• Reliance on third-party licensors and the ability to preserve and protect intellectual property rights are critical.
• Significant competition from other biotechnology and pharmaceutical companies exists.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern, requiring additional capital to finance operations beyond the second quarter of fiscal year 2025.
• A failure to obtain necessary capital in the near term on acceptable terms, or at all, could force the company to delay, limit, reduce, or terminate development programs, commercialization efforts, or other operations.

Future Outlook

Actuate Therapeutics plans to engage with regulatory authorities (FDA, EMA) to discuss the requirements for a registration-type trial in first-line metastatic pancreatic cancer, potentially a confirmatory trial given the compelling Phase 2 data. The company is also exploring further development of elraglusib in earlier stages of pancreatic cancer (localized, resectable, borderline resectable disease), in combination with other agents like RAS inhibitors and immune checkpoint inhibitors, and for other GI cancers (colon, gastric, biliary) and lung cancer. An oral tablet formulation is under development to enable longer-term and home-based treatment.

Management Comments

• Daniel Schmitt, President & CEO: "The trial represents a major milestone in our development of elraglusib."
• Dr. Colin Weekes, Director of Pancreatic Research: "For the first time, seeing an overall survival benefit... The magnitude of that benefit, I think, is actually substantial."
• Dr. Deva Mahalingam, Principal Investigator: "I'm surprised, I can tell you when I started the study, you know, and we are as physician, we want to see response and shrinkage of tumor. But then when we start seeing patients that are still in the study one year on, we're going like, what's going on here with this treatment."
• Dr. Rachna Shroff, GI Medical Oncology Leader: "It wasn't necessarily... complicated to be able to put patients on this trial and offer them this drug, which I think is really, really important."
• Dr. Tanios Bekaii-Saab, Chair of Hematology and Medical Oncology: "In pancreas terms, this is a big differential. And the tail of the curve that's forming actually is even more impressive. The fact that you have a doubling of the landmark survival is pretty impressive itself."
• Dr. Colin Weekes: "I think what this drug does, the safety profile we're talking about, it now runs for combinability. It becomes a platform that you can add to."
• Dr. Tanios Bekaii-Saab: "This is one of the, if not the first biologic, immune-based therapy that its biology and immunology together in this that essentially drove the study to be positive. We haven't seen that for a long, long time in pancreas cancer."
• Dr. Deva Mahalingam: "Anything above three months, I think would be kind of significant... that would usually translate with a hazard ratio kind of less than 0.7."
• Dr. Deva Mahalingam: "I would give all my patients gem/abraxane with this drug because of the survival benefit that you see."
• Dr. Colin Weekes: "I would give it to every patient."

Industry Context

Pancreatic cancer is widely recognized as one of the most challenging cancers to treat, with historically poor survival rates and limited therapeutic advancements. The current standard first-line chemotherapy backbones, FOLFIRINOX (from 2011) and gemcitabine/nab-paclitaxel (from 2013), have seen little improvement in outcomes despite numerous negative trials. Newer regimens like NALIRIFOX have shown only marginal benefits with significant toxicity, limiting adoption. Actuate's elraglusib, as a GSK-3 beta inhibitor with immunomodulatory effects, represents a novel biological approach, distinct from traditional cytotoxic chemotherapy or prior failed immunotherapies in pancreatic cancer. Its demonstrated overall survival benefit and favorable tolerability profile position it as a potentially transformative agent in a landscape desperate for innovation.

Comparison to Industry Standards

• The observed 4-month median overall survival benefit with elraglusib plus GnP in the evaluable patient population is considered substantial in pancreatic cancer, where major advances have been rare since 2013.
• The hazard ratio for OS, implied to be less than 0.5, is significantly better than the 0.7-0.8 hazard ratios typically considered positive in pancreatic cancer trials.
• Unlike NALIRIFOX, which showed only marginal benefit and is associated with severe toxicity (less than 2% market share), elraglusib demonstrated significant OS benefit with a highly tolerable safety profile, making it more combinable and potentially more widely adopted.
• The study's ability to show an OS benefit despite similar PFS is consistent with patterns seen in successful immunotherapy trials (e.g., KEYNOTE-048 in head-and-neck cancer, and certain lung cancer trials), suggesting a durable immune-mediated effect and post-progression benefit, which is a novel finding for pancreatic cancer.
• The tolerability of elraglusib, even in combination with FOLFIRINOX (a notoriously challenging regimen), contrasts with many other investigational agents that have failed due to overlapping toxicities with chemotherapy backbones.

Stakeholder Impact

• **Shareholders:** Highly positive impact due to strong clinical data, which significantly de-risks the drug's development and potential market entry, potentially increasing company valuation and attracting investment, despite the stated need for capital.
• **Patients:** Extremely positive impact, as elraglusib offers a significant and well-tolerated improvement in overall survival for metastatic pancreatic cancer, a disease with very limited effective treatments.
• **Employees:** Positive impact due to the success of a key pipeline asset, potentially leading to increased job security and growth opportunities within the company.
• **Healthcare Providers/Medical Community:** Positive impact, as the drug provides a new, effective, and tolerable treatment option for a challenging patient population, potentially changing clinical practice and offering new hope.
• **Creditors:** The positive clinical data may improve the company's ability to secure future financing, potentially reducing perceived credit risk, though the going concern warning remains relevant.

Next Steps

• Engage in discussions with regulatory authorities (FDA, EMA) to determine the requirements for a registration-type trial for elraglusib in first-line metastatic pancreatic cancer.
• Strategically decide on eligibility criteria for future trials to mitigate early patient drop-off observed in the Phase 2 study.
• Continue development of an oral tablet formulation of elraglusib for potential longer-term and home-based treatment.
• Explore further clinical development of elraglusib in earlier stages of pancreatic cancer (e.g., localized, resectable, borderline resectable disease).
• Initiate or advance trials combining elraglusib with RAS inhibitors and immune checkpoint inhibitors.
• Investigate the applicability of elraglusib in other GI cancers (colon, gastric, biliary) and lung cancer, given its multifaceted mechanism of action.

Key Dates

Recommendation

Keywords

Pancreatic Cancer, Metastatic Pancreatic Cancer, mPDAC, Elraglusib, GSK-3 beta inhibitor, Clinical Trial, Phase 2, Oncology, Chemotherapy, Immunotherapy, Overall Survival, ASCO, Drug Development, Biomarker, EMT, Cancer Treatment